Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AST-008 in Healthy Subjects
NCT03086278Phase 1Completed
- Sponsor
- Exicure, Inc.
- Start
- Oct 2017
- Primary completion
- Aug 2018
- Modality
- Antisense DNA, Nanoparticles, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 1, randomised trial of cavrotolimod in Merkel cell carcinoma (MCC), cutaneous squamous cell carcinoma (cSCC), melanoma and 1 more, sponsored by Exicure, Inc. Primary endpoints: Serious related adverse events at 1 month and Adverse events at 1 month. Started Oct 2017; status: completed.
02
Drugs
cavrotolimod
03
Conditions
Merkel cell carcinoma (MCC)cutaneous squamous cell carcinoma (cSCC)melanomasolid tumor
Beyond the preview
Go deeper on NCT03086278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03086278.